A disproportionality analysis of adverse events associated with omadacycline based on the FDA adverse event reporting system database
Eine Disproportionalitätsanalyse von mit Omadacyclin assoziierten unerwünschten Ereignissen auf Basis der FDA Adverse Event Reporting System-Datenbank
Journal of Antimicrobial Chemotherapy · 19.01.2026 · 81 (2)
DOI: 10.1093/jac/dkag006 ↗Auf einen Blick
In FAERS wurden 4541 Meldungen zu Omadacyclin analysiert. Häufig gemeldet wurden Übelkeit, Erbrechen und Diarrhö; die stärksten Signale betrafen Zahn- und Zungenverfärbung.
Fragestellung
Welche unerwünschten Arzneimittelwirkungen von Omadacyclin zeigen Signale im FDA Adverse Event Reporting System (FAERS)?
Methode
Auswertung von Post-Marketing-ADR-Meldungen in FAERS vom 1. Quartal 2020 bis zum 4. Quartal 2024; Disproportionalitätsanalyse mit 4 Methoden.
Ergebnisse
4541 omadacyclinbezogene Meldungen, 577 verschiedene ADRs. Häufig: Übelkeit 221 (14,1 %), Erbrechen 129, Diarrhö 93, Dyspnoe 56, Rash 52. Stärkste Signale: Zahnverfärbung, Zungenverfärbung und Mycobacterium-avium-complex-Infektion.
Schlussfolgerung der Autor:innen
Omadacyclin war mit gastrointestinalen Beschwerden, Zahnverfärbung und respiratorischen Komplikationen assoziiert. Auf hepatische Schäden und Mortalität sollte besonders bei älteren multimorbiden Patient:innen geachtet werden.
Kernaussagen
- 4541 Meldungen zu Omadacyclin in FAERS
- Häufigste ADRs: Übelkeit, Erbrechen, Diarrhö
- Stärkste Signale: Zahn- und Zungenverfärbung
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 23.01.2026. Verfasst von Ye-Lei Zhao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha 410011, China. Hauptthemen laut MEDLINE: Adverse Drug Reaction Reporting Systems, Tetracyclines, Anti-Bacterial Agents, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Degree & Postgraduate Education Reform Project of Central South University.
Themen: Patientensicherheit
Abstract (Originalsprache)
Objective
Omadacycline, a novel aminomethylcycline antibiotic for community-acquired bacterial infections, lacks comprehensive real-world safety data. We evaluated its adverse drug reactions (ADRs) using the FDA Adverse Event Reporting System (FAERS).
Methods
A comprehensive analysis of post-marketing ADR reports submitted to FAERS between the first quarter of 2020 and the fourth quarter of 2024 was conducted. Disproportionality signals were assessed via four methods: reporting odds ratio (ROR), proportional reporting ratio, Bayesian confidence propagation neural network and multi-item gamma Poisson shrinker. Results and conclusion Among 4541 omadacycline-related reports, 577 distinct ADRs were identified. The most frequently reported ADRs were nausea (221 cases, 14.1%), vomiting (129), diarrhoea (93), dyspnoea (56) and rash (52). The strongest safety signals (ROR) included tooth discolouration (ROR = 184.33, 95% CI = 96.79–351.06), tongue discolouration (159.88, 101.76–251.25) and Mycobacterium avium complex infection (73.30, 40.15–133.78). Hepatic events (e.g. elevated transaminases) and mortality (49 cases) also demonstrated significant signals. Omadacycline is associated with gastrointestinal disturbances, dental discolouration and respiratory complications. Vigilance for hepatic injury and mortality is warranted, especially in elderly comorbid patients. Ongoing pharmacovigilance integrating real-world evidence is essential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha 410011, China.
- Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410078, China.
- Hunan Key Laboratory of the Research and Development of Novel Pharmaceutical Preparations, Changsha Medical University, Changsha 410219, China.
ORCID-Profile: Jian Qu
Förderung
- Degree & Postgraduate Education Reform Project of Central South University
Zitieren
APA
Zhao, Y. L., Qu, Q., Wang, Y. M., Zhang, Y. T., & Qu, J. (2026). A disproportionality analysis of adverse events associated with omadacycline based on the FDA adverse event reporting system database. Journal of Antimicrobial Chemotherapy, 81(2). https://doi.org/10.1093/jac/dkag006
Vancouver
Zhao YL, Qu Q, Wang YM, Zhang YT, Qu J. A disproportionality analysis of adverse events associated with omadacycline based on the FDA adverse event reporting system database. Journal of Antimicrobial Chemotherapy. 2026;81(2). doi:10.1093/jac/dkag006
BibTeX
@article{Zhao2026,
author = {Zhao, Ye-Lei and Qu, Qiang and Wang, Yi-Ming and Zhang, Yan-Tao and Qu, Jian},
title = {A disproportionality analysis of adverse events associated with omadacycline based on the FDA adverse event reporting system database},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
volume = {81},
number = {2},
doi = {10.1093/jac/dkag006}
}
EUVIMED